AdjuderaCommencer

Attribution

LOT 6: Innovative technologies for manufacturing and quality control of medicines

Langue d’origine: anglais

Suivre cette ficheAvec Adjudera Pro, soyez alerté avant qu’un marché n’arrive à échéance.
Acheteur
European Medicines Agency, MED - European Medicines Agency
Titulaires
NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED, RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH, UNIVERSITA DEGLI STUDI DI MILANO
Montant du marché
aucun montant publié
Offres reçues
4
Publié le
1 sept. 2026
Attribution
17 mars 2026
Début d'exécution
17 mars 2026
Fin du marché
15 mars 2028estimée
Secteur
Recherche et développement
Région
Groot-Amsterdam
Source
Avis d'origine sur TED (606784-2026)

Autres attributions de cet acheteur

AttributionAcheteurTitulaireMontant du marchéPublié le
Data Management- Anonymization and redaction of documents and datasetsEuropean Medicines Agency, MED - European Medicines AgencyIQVIA Solutions Belgium B.V., Syneos Health Clinical Spain, S.L.U.—4 sept. 2026
LOT 7: Computational methods for comparison of molecular structural features in the context of medicines for rare diseasesEuropean Medicines Agency, MED - European Medicines AgencyIstituto di Ricerche Farmacologiche Mario Negri, KREATIS—1 sept. 2026
LOT 5: Pharmacoepidemiological researchEuropean Medicines Agency, MED - European Medicines AgencyAgora Labs S.r.L., Biomedical Research Foundation, Academy of Athens – BRFAA, Certara France SARL +15 autres—1 sept. 2026
LOT 4: Qualitative researchEuropean Medicines Agency, MED - European Medicines AgencyNHG Finland Oy, NIVEL, Oracle France S.A.S. +2 autres—1 sept. 2026
LOT 3: Methodological/statistical researchEuropean Medicines Agency, MED - European Medicines AgencyAgentschap College ter Beoordeling van Geneesmiddelen, Austrian Agency for Health and Food Safety GmbH, Danish medicines Agency +8 autres—1 sept. 2026
LOT 2: Veterinary researchEuropean Medicines Agency, MED - European Medicines AgencyDanish medicines Agency, Ecorys Europe EEIG - GEIE, Gent university—1 sept. 2026